Alkem Laboratories Limited
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
What Alkem files
- Others96
- Investor Meet62
- Updates42
- Important22
- PPTs11
- Board Meeting11
Alkem Laboratories has launched Renocia Exo™, India’s first patented Ginsenoside Exosome-based hair growth serum. This advanced regenerative therapy targets hair follicle vitality, scalp health, and cellular signalling pathways, strengthening the company's dermatology portfolio for managing rising hair loss concerns.
Alkem's Board approved Q4 and full-year financial results, proposing a final dividend of Rs. 10 per share for FY26. Payment for the declared dividend is set from September 1. The Board also approved the re-appointment of an Executive Director for five years.
Alkem Laboratories secured 30 acres in Ujjain for a new greenfield formulations manufacturing facility. The company's board approved an investment of up to INR 533 crores, to be made in a phased manner.
Alkem Labs is expanding its global footprint by establishing a new subsidiary in Saudi Arabia. The company will hold a 51% majority stake in this new venture, with a local partner holding 49%. This strategic move aims to significantly extend Alkem's business and market reach into the Kingdom of Saudi...
Alkem Laboratories has received stock exchange approval for reclassifying four promoter group members to the public category. This reclassification involves 22 lakh (0.22 Cr) shares. Post-approval, the promoter holding will decrease from 55.13% to 53.29%, while public holding will increase from 44.87% to 46.71%. This move enhances the public float...